Displaying 1 - 6 of 6
| Active Ingredient | NATEGLINIDE |
| Therapeutic Class | MEGLITINIDES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | REPAGLINIDE |
| Therapeutic Class | MEGLITINIDES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | Metformin/Empagliflozin |
| Therapeutic Class | Sodium Glucose Co-Transporter Inhibitor |
| Indications |
Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with other antidiabetic drugs or insulin. Empagliflozin, when used in combination with metformin, is also ind More ... |
| Caution | Urinary tract infection ,Decreased vitamin B12 levels; Female genital mycotic infections ;Increased urination ;Male genital mycotic infections; Necrotizing fasciitis of the perineum (Fournier’s gangre More ... |
| Dose Range |
Empagliflozin total daily dose: 10 mg For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |
| Active Ingredient | DAPAGLIFLOZIN |
| Therapeutic Class | SODIUM-GLUCOSE COTRANSPORTER INHIBITOR |
| Indications | As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus |
| Caution | Back pain; balanoposthitis; dizziness; dyslipidaemia; hypoglycaemia (in combination with insulin or sulphonylurea); increased risk of genital mycotic infection in both males and females; rash; increas More ... |
| Dose Range | The usual oral dose is 5 or 10 mg once daily. Doses of insulin, sulfonylurea, and other insulin secretagogues may need to be lowered when used with dapagliflozin. The dose of dapagliflozin should be reduced in hepatic impairment. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DAPAGLIFLOZIN | METFORMIN |
| Therapeutic Class | SODIUM-GLUCOSE COTRANSPORTER INHIBITOR |
| Indications | As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. |
| Caution | Back pain; balanoposthitis; dizziness; dyslipidaemia; hypoglycaemia (in combination with insulin or sulphonylurea); increased risk of genital mycotic infection in both males and females; rash; increas More ... |
| Dose Range | The usual oral dose is 5 or 10 mg once daily. Doses of insulin, sulfonylurea, and other insulin secretagogues may need to be lowered when used with dapagliflozin. The dose of dapagliflozin should be reduced in hepatic impairment. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EMPAGLIFLOZIN |
| Therapeutic Class | SODIUM-GLUCOSE COTRANSPORTER INHIBITOR |
| Indications | Monotherapy or with other antidiabetic medications, including insulin, in the management of type 2 diabetes mellitus; To reduce the risk of cardiovascular death in those with type 2 diabetes mellitus More ... |
| Caution | Urinary tract infection, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, female genital mycotic infections, male genital mycotic infections, and nausea |
| Dose Range | The usual oral dose of empagliflozin is 10 mg once daily, which may be increased to 25 mg daily, if necessary. When given with metformin, empagliflozin may be given in 2 divided doses. Doses of insulin, sulfonylurea, or other insulin secretagogues may nee |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |